Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Octave Bioscience, Inc.
Octave Bioscience to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave Bioscience to Participate in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
November 10, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave Bioscience Awarded Valhalla Foundation Grant to Accelerate Development of the First MS Disease Progression Test
October 06, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave Bioscience Announces $35M Series C Financing to Accelerate Commercial Momentum
September 04, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave Bioscience to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
August 28, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave Bioscience Expands Medical Leadership to Accelerate Precision Care in Neurodegenerative Disease
May 29, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave MSDA Test Gains NY State Certification, Expanding Access Nationwide
April 29, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave Bioscience’s MSDA Test Proven to Provide Clinically Actionable Insights That Drive Meaningful Clinical Decisions in MS Care
April 16, 2025
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience Continues Commercial Momentum with Addition of Accomplished CFO Marcel Konrad
August 07, 2024
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience, Inc. Announces Publication in Nature Communications
May 29, 2024
From
Octave Bioscience, Inc.
Via
Business Wire
Octave Bioscience Accelerates Leadership in Precision Care for Neurodegenerative Diseases with Addition of World-Class Commercial Executives
March 28, 2024
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience, Inc. Announces Chairman of the Board, CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for its Precision Care Solution
December 05, 2023
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience, Inc. Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate Multi-Analyte Protein Biomarker Test for Parkinson’s Disease Assessments
November 15, 2023
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience, Inc. Presents Data Highlighting Application and Impact of its Precision Care Solution at MSMilan2023
October 11, 2023
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management
September 06, 2023
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience, Inc. Announces Publication of Clinical Validation Study Results of its Novel, Multivariate Multiple Sclerosis Disease Activity (MSDA) Blood Test
August 30, 2023
From
Octave Bioscience, Inc.
Via
Business Wire
Octave® Bioscience, Inc.’s Solution for Transforming the Care Paradigm in MS has been Selected as a Finalist in Fast Company’s 2023 Innovation by Design Awards
August 24, 2023
From
Octave Bioscience, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.